Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
BOSTON, April 11, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VERVE-102 for the treatment of patient groups with hyperlipidemia and high lifetime cardiovascular risk to reduce low-density lipoprotein cholesterol (LDL-C). VERVE-102 is the company's novel, in vivo, investigational base editing medicine designed to be a single-course treatment that permanently turns off the PCSK9 gene in the liver and durably reduces disease-driving LDL-C. VERVE-102 is currently being tested in the Phase 1b Heart-2 clinical trial, which is designed to evaluate the safety and tolerability of VERVE-102 administration in adult patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD) who require additional lowering of LDL-C.
'Despite available treatment options to lower LDL-C, there remains a pressing need to provide sustained LDL-C lowering and thereby, improve efficacy," said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve Therapeutics. 'Nearly 50% of patients discontinue prescribed LDL-C-lowering therapy within a year. Verve has long understood that profound, sustained LDL-C lowering is key to transforming the treatment of atherosclerotic cardiovascular disease. As a potential one-dose treatment, we believe VERVE-102 is uniquely designed to address this unmet need. We look forward to collaborating with the FDA as we work to deliver this paradigm-shifting treatment to patients.'
The FDA's Fast Track designation is designed to facilitate the development and expedite the review of drugs that are intended to treat serious or life-threatening conditions and demonstrate the potential to address an unmet medical need. A drug that receives Fast Track designation may be eligible for more frequent meetings and communications with the FDA and rolling review of any application for marketing approval. A drug receiving Fast Track designation also may be eligible for Priority Review if relevant criteria are met.
In the second quarter of 2025, Verve expects to announce demographic and initial safety and efficacy data from the Heart-2 clinical trial. The initial data set is expected to include participants across the first three dose cohorts (0.3 mg/kg, 0.45 mg/kg, and 0.6 mg/kg) with at least 28 days of follow-up for each participant.
In addition, in the second half of 2025, Verve remains on track to report the final data for the dose escalation portion of the Heart-2 clinical trial, deliver the opt-in package for the PCSK9 program to Eli Lilly and Company (Lilly), and initiate the Phase 2 clinical trial for the PCSK9 program.
About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The company's lead programs – VERVE-102, VERVE-201, and VERVE-301 – target the three cholesterol drivers of atherosclerosis: LDL-C, remnant cholesterol, and Lp(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia (HoFH). VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels. Lp(a) is a genetically validated, independent risk factor for ASCVD, ischemic stroke, thrombosis, and aortic stenosis. For more information, please visit www.VerveTx.com.
Cautionary Note Regarding Forward Looking StatementsThis press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the company's ongoing Heart-2 clinical trial; the timing and availability of data for the Heart-2 trial and timing for initiation of the Phase 2 clinical trial for the PCSK9 program; the timing of delivery of the opt-in package to Lilly; the potential advantages and therapeutic potential of the company's programs; and expectations regarding the potential benefits of Fast Track designation. All statements, other than statements of historical facts, contained in this press release, including statements regarding the company's strategy, future operations, future financial position, prospects, plans and objectives of management, are forward-looking statements. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the company's limited operating history; the company's ability to timely submit and receive approvals of regulatory applications for its product candidates; advance its product candidates in clinical trials; initiate, enroll and complete its ongoing and future clinical trials on the timeline expected or at all; correctly estimate the potential patient population and/or market for the company's product candidates; replicate in clinical trials positive results found in preclinical studies and/or earlier-stage clinical trials of VERVE-101, VERVE-102, and VERVE-201; advance the development of its product candidates under the timelines it anticipates in current and future clinical trials; obtain, maintain or protect intellectual property rights related to its product candidates; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the company's actual results to differ from those contained in the forward-looking statements, see the 'Risk Factors' section, as well as discussions of potential risks, uncertainties and other important factors, in the company's most recent filings with the Securities and Exchange Commission and in other filings that the company makes with the Securities and Exchange Commission in the future. In addition, the forward-looking statements included in this press release represent the company's views as of the date hereof and should not be relied upon as representing the company's views as of any date subsequent to the date hereof. The company anticipates that subsequent events and developments will cause the company's views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so.
Investor ContactJen RobinsonVerve Therapeutics, Inc.jrobinson@vervetx.com
Media ContactAshlea Kosikowski1ABashlea@1abmedia.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
an hour ago
- Indianapolis Star
Cannabis users 29% more likely to experience heart risks, new study shows
A new study builds on previous research that shows marijuana usage can contribute to cardiovascular risks. Research published in Heart, an international peer-reviewed journal, documents that adults who use cannabis are 29% more likely than nonusers to develop Acute Coronary Syndrome and 20% more likely than nonusers to suffer from stroke. Acute Coronary Syndrome is any condition brought on by a reduction or blockage of blood flow to the heart, which can result in heart attacks. Researchers surveyed 24 studies conducted between 2016 and 2023 that involved more than 400 million participants, ranging mostly between 19 and 59, according to the study. "Our findings are consistent with those from previous reviews, which outlined a positive association between cannabis use and cardiovascular disorders," the study states. "The increased awareness of this potential risk among cannabis users should encourage investigating such use in all patients presenting with serious cardiovascular disorders." Marijuana news: New study finds cannabis edibles raise risk of premature heart disease Simply put, not enough research has been conducted to determine just how marijuana affects the cardiovascular system. The research that has been done has largely been conducted on the effects of smoking cannabis, in contrast to other modes of consumption like edibles. But generally, researchers understand that marijuana can make the heart beat faster and raise blood pressure, as reported by the Centers for Disease Control and Prevention (CDC). Ahmed Mahmoud, a clinical instructor at Boston University, previously told USA TODAY that researchers believe marijuana may make small defects in the coronary arteries' lining, the thin layer of cells that forms the inner surface of blood vessels and hollow organs. "Because cannabis increases the blood pressure and makes the blood run very fast and make some detects in the lining to the coronary arteries, this somehow could make a thrombosis (formation of a blood clot) or a temporary thrombosis in these arteries, which makes a cardiac ischemic (stroke) or the heart muscle is not getting enough oxygen to function," Mahmoud previously told USA TODAY. "This is what makes the heart injured and this is a myocardial infarction or heart attack." Terms to know: Is marijuana the same as cannabis? What is THC? The new study aligns with previous research about cannabis' effects on the cardiovascular system. A study published earlier this year found that people under the age of 50 who consume marijuana are about 6.2 times more likely to experience a heart attack than nonusers. Young marijuana users are also 4.3 times more likely to experience an ischemic stroke and 2 times more likely to experience heart failure, the study shows. And a study published in the Journal of the American Heart Association last year found the same, that cannabis users are more likely to experience cardiovascular risks than those who do not partake.
Yahoo
2 hours ago
- Yahoo
Gilead's twice-yearly HIV prevention injection gets FDA approval
The US Food and Drug Administration has approved Gilead's (GILD) new HIV prevention drug. The drug, lenacapavir, only requires an injection every 6 months. Yahoo Finance Healthcare Reporter Anjalee Khemlani reports the details. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. What's a big milestone for Gilead Sciences today. The Biotech Giant securing FDA approval for its latest HIV treatment. It's a significant step forward for that company and patients. Gilead also seeing a boost on that news. Our senior health reporter Anjali kamlani joins us now. Au, what is what is the big takeaway for for investors watching all this? Yeah, I think the big takeaway here is that investors have actually been waiting for this approval. They anticipate quick uptake and a high volume of uptake of this drug used as a pre-exposure prophylaxis, you know, prep as the common acronym for those types of drugs. Now, Gilead already has discovy for that, but the difference here is that this new use or new approval for Lenca Paviar, it is a twice yearly injectable. And that is the difference between the regular oral and this new approval. And so that is really going to help boost Gilead's revenues for the year. We know that already Lenca Paviar brings in about $60 million for the company, and they're anticipating that that will get boosted to about $150 to $195 million in revenue for the company for the year. That's the estimate that analysts are expecting with the approval, and they've been waiting for this approval for quite some time. So really good news. You can see that, you know, the stock is benefiting from this right now and is supposed to be a game changer for those patients. There are some questions about whether or not being a twice yearly drug, it will be more expensive than say a daily oral. And so that is something that Gilead has tried to addressing that they plan to have a insurance and non-insurance access point for patients as well. Thanks so much for joining us on this. Appreciate it. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Insider
2 hours ago
- Business Insider
Cellectar Biosciences announces 1-for-30 reverse stock split
Cellectar Biosciences (CLRB) announced a one-for-thirty reverse stock split of the company's common stock, par value $0.00001, which will become effective on Tuesday, June 24. The company's common stock will continue to trade under its current trading symbol, CLRB, on Nasdaq on a split-adjusted basis when the market opens on Tuesday, June 24, with the new CUSIP number 15117F880. As a result of the Reverse Stock Split, every 30 shares of the company's pre-split common stock issued and outstanding will be automatically reclassified into one new share of the company's common stock. The Reverse Stock Split will reduce the number of shares of common stock issued and outstanding from 54,361,197 shares to approximately 1,812,040. There will be no change to the number of authorized shares or the par value per share. The Reverse Stock Split will affect all stockholders uniformly and will not alter any stockholder's percentage ownership interest. As a result of the Reverse Stock Split, the number of shares of common stock available for issuance under the company's equity incentive plans will be proportionately affected. Confident Investing Starts Here:
